PV Bulletin

Aidacare Aspire Active Air 8 Pressure Care Air Mattress

Aidacare Pty Ltd has updated the user manual for the Aspire Active Air 8 Pressure Care Mattress to add setup instructions and warnings about using the device in the presence of oxygen enriched environments.

Primary source: Safety monitoring and information

PV Impact Brief

Urgency: HighConfidence: high

What changed

The user manual has been modified to add specific setup instructions and important warnings.

Why it matters

This update is crucial as it could significantly impact the usability and safety of the device, particularly in environments where oxygen levels are elevated.

Action needed

Review and update the labeling and training materials to include new user manual information for the Aspire Active Air 8 Pressure Care Mattress.

Relevant for
Labeling LeadRegulatory Intelligence Lead
Processes impacted
LabelingInspection Readiness
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 10, 2026

Full briefing

Practical implication

Review and update the labeling and training materials to include new user manual information for the Aspire Active Air 8 Pressure Care Mattress.

The user manual for the Aidacare Aspire Active Air 8 Pressure Care Mattress has been updated to include critical setup instructions and warnings regarding usage in oxygen-enriched environments.

What changed: The user manual has been modified to add specific setup instructions and important warnings.

Why it matters: This update is crucial as it could significantly impact the usability and safety of the device, particularly in environments where oxygen levels are elevated.

Practical implication: Review and update the labeling and training materials to include new user manual information for the Aspire Active Air 8 Pressure Care Mattress.

View original source

  • Source: TGA Safety Alerts - Market actions feed
  • Published at source: 2026-09-10T00:00:00.000Z
  • Discovered by monitor: 2026-09-10T21:30:22.417Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Labeling#Safety Signals#Australia#Source-ingestion#Regulator-monitor#Tga.gov.au

Related updates for your role

publicFDA · USA · Updated Sep 10, 2026

Epidural Kit Correction: Medical Action Industries Issues Correction for Epidural Kits Containing Spectra Medical Devices Lidocaine Ampules

Urgency: High

Healthcare providers should quarantine all impacted epidural kits and remove any sodium chloride ampules affected by this recall, implementing corrective actions per FDA guidance.

Signal ManagementInspection ReadinessRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 9, 2026

Guidelines on good pharmacovigilance practices (GVP): Introductory cover note, revision 2 of Module III on pharmacovigilance inspections

Urgency: High

Ensure that all inspection readiness protocols are updated to align with the new guidelines from revision 2 of Module III and incorporate implementation regulations effective from 12 February 2026.

Inspection ReadinessPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 9, 2026

XEVPRM User Guidance Version 3.21 Update

Urgency: High

Review the updated guidance to incorporate the new compliance procedures starting from 1 January 2026, specifically regarding the electronic submission process.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Sep 9, 2026

Electronic submission of Article 57(2) data: questions and answers

Urgency: High

Marketing authorization holders must implement processes to ensure timely submissions of required data within the defined 15 and 30 calendar day timelines, including details of the Qualified Person responsible for Pharmacovigilance and the submission of Pharmacovigilance System Master File information.

ICSRRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward